Tenofovir News and Research

RSS

Tenofovir associated with significant risk of kidney damage and chronic kidney disease

Tenofovir, one of the most effective and commonly prescribed antiretroviral medications for HIV/AIDS, is associated with a significant risk of kidney damage and chronic kidney disease that increases over time, according to a study of more than 10,000 patients led by researchers at the San Francisco VA Medical Center and the University of California, San Francisco (UCSF).

13 Feb 2012

Positive data from Chimerix CMX001 Phase 2 study on CMV disease

Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.

6 Feb 2012

Positive results from Chimerix CMX001 study for CMV in hematopoietic stem cell transplant recipients

6 Feb 2012

African scientists' search for female-controlled microbicide gel to prevent HIV continues

AllAfrica.com examines efforts by African researchers to develop a female-controlled HIV prevention method, writing, "Scientists searching for a gel or vaccine that can prevent HIV infection ride a rollercoaster of hope and disappointment." The article profiles efforts by researchers from the Centre for the AIDS Program of Research in South Africa (Caprisa) to find a microbicide gel to protect women from HIV infection.

4 Feb 2012

AHF calls for top to bottom shake-up of management at FDA

AIDS Healthcare Foundation (AHF) today called for a top to bottom shake-up of the management at the Food and Drug Administration as well as a Congressional investigation following the publication of a Washington Post news article (1/31/12) that reported, "…the Food and Drug Administration secretly monitored the personal e-mail of a group of its own scientists and doctors after they warned Congress that the agency was approving medical devices that they believed posed unacceptable risks to patients."

3 Feb 2012

Gilead commences GS-7340 Phase 2 trial in HIV

Gilead Sciences, Inc. today announced the initiation of a Phase 2 clinical trial evaluating GS-7340 for the treatment of HIV-1 infection in treatment-naïve adults. GS-7340 is a novel prodrug of tenofovir, the active agent in Viread.

24 Jan 2012

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12.

19 Jan 2012

FDA accepts Gilead's Quad HIV regimen NDA for review

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Quad, a complete single-tablet HIV regimen containing elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.

26 Dec 2011

WHO approves three Mylan ARV therapies to treat HIV/AIDS

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received approval for three antiretroviral (ARV) therapies used to treat HIV/AIDS under the World Health Organization's (WHO) Prequalification of Medicines Programme. The products include:

20 Dec 2011

Testing of vaginal gel for HIV prevention halted after interim results showed no difference from placebo

Researchers involved with a multi-armed clinical trial designed to evaluate different antiretroviral (ARV) interventions for HIV prevention on Friday announced the arm testing a vaginal gel had been stopped because it was not working, the New York Times reports.

29 Nov 2011

VOICE continues testing daily use of ARV Truvada among women in sub-Saharan Africa

VOICE, an HIV prevention trial that has been evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women - daily use of one of two different ARV tablets or of a vaginal gel - has stopped testing the gel.

29 Nov 2011

Tenofovir gel no more effective than placebo gel in preventing HIV

An independent review of the VOICE study, funded by the National Institute of Allergy and Infectious Diseases (NIAID) and conducted by the Microbicide Trials Network, determined that tenofovir gel was no more effective than placebo gel in preventing HIV.

28 Nov 2011

First clinical trial of dapivirine-maraviroc ring to treat HIV in women

In the first clinical trial of a vaginal ring combining two antiretroviral (ARV) drugs, researchers from the Microbicide Trials Network (MTN) are collaborating with the International Partnership for Microbicides (IPM) to evaluate whether the ring is safe for use in women.

16 Nov 2011

Gilead submits Quad NDA to FDA for treatment of HIV-1 infection

Gilead Sciences, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of the "Quad", a complete single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.

28 Oct 2011

Anti-HIV vaginal gel could also reduce genital herpes by half: Study

The study appears this week in the journal Cell Host & Microbe that tested the gel on women in South Africa (where the risk of HIV and herpes is great) found that the anti-HIV/AIDS drug tenofovir reduced herpes infections by 51% and HIV infections by 39%.

24 Oct 2011

Tenofovir gel confirmed to be effective against herpes in lab experiment, study shows

Data from lab experiments published online by the journal Cell Host and Microbes last week show that the gel form of the antiretroviral tenofovir, which is being investigated as an HIV prevention method, works to inhibit the reproduction of herpes virus in tonsil and cervical tissue, the New York Times reports.

24 Oct 2011

Tenofovir gel shows promise against HSV infection

HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, it would be highly beneficial to identify multi-faceted microbicide compounds that are efficient against HIV-1 and other sexually transmitted infections.

20 Oct 2011

USAID award supports study of SILCS diaphragm plus tenofovir gel on HIV, HSV

USAID awarded CONRAD a five year project with a $2 million ceiling to focus on testing the safety and effectiveness of the SILCS diaphragm, the one-size-fits-most contraceptive barrier, combined with tenofovir gel -- the only topical product proven to prevent the acquisition of HIV and Herpes Simplex Virus.

14 Oct 2011

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck, known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated adult HIV-1-infected patients.